title: Lung resection for bronchogenic carcinoma after pneumonectomy: a safe and worthwhile procedure.
abstract: OBJECTIVE
  Patients treated surgically for lung cancer can develop either a metachronous cancer or a recurrence. The appearance of a new cancer on the remaining lung after a pneumonectomy poses unique treatment problems, and surgery is often considered contraindicated. We report on the outcome of resections for lung cancer after pneumonectomy performed for lung cancer.
  
  
  METHODS
  We reviewed the records of patients who underwent a resection of bronchogenic carcinoma on the remaining lung from 1990 to 2002.
  
  
  RESULTS
  There were 14 patients (13 males and 1 female) with a median age of 64 years (range 51-74). Median preoperative Fev1 was 1.45 (range 1.35-2.23), corresponding to 59% of predicted Fev1 (range 46-80%). Resection was performed between 11 and 264 months after pneumonectomy (median 35.5). The resections performed were: one wedge resection in 11 patients, two wedge resections in two patients and two segmentectomies in two other patients; one patient underwent a third resection. Diagnosis was metachronous cancer in 12 patients and metastasis in two patients. Complications occurred in three patients (21%), while operative mortality was nil. Mean hospital stay was 10.5 days (6-25). Two patients received chemotherapy (one after local recurrence, one after the third resection). Overall 1, 3 and 5 year survivals were 57, 46 and 30%, respectively (median 21 months). For patients with a metachronous cancer they were 69, 55 and 37% (median 57 months), respectively, while neither patient with a metastatic tumor survived 1 year (P=0.03).
  
  
  CONCLUSIONS
  Limited lung resection on a single lung is a safe procedure associated with acceptable morbidity and mortality rates. In patients with a metachronous lung cancer, long-term survival with a good quality of life can be obtained with limited resection on the residual lung.
authors.affiliation: Operative Unit of Thoracic Surgery, Ospedale Maggiore, Azienda Ospedaliera Verona, P.le Stefani 1, 37126 Verona, Italy. alterzi@libero.it
authors.forename: A
authors.initials: A
authors.lastname: Terzi
authors.forename: A
authors.initials: A
authors.lastname: Lonardoni
authors.forename: P
authors.initials: P
authors.lastname: Scanagatta
authors.forename: S
authors.initials: S
authors.lastname: Pergher
authors.forename: C
authors.initials: C
authors.lastname: Bonadiman
authors.forename: F
authors.initials: F
authors.lastname: Calabrò
mesh_terms: D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D007902:Length of Stay; D008175:Lung Neoplasms / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000601:surgery*; D010101:Oxygen Consumption; D011013:Pneumonectomy / Q000379:methods*; D011183:Postoperative Complications / Q000601:surgery*; D012086:Reoperation